Back in February we identified eleven potential blockbusters on track for approval in 2020. At this point, five have been approved and six are in need of additional data from trials before the FDA will grant approval. The five approvals covered the following indications: migraine, relapsing multiple sclerosis (2 drugs), breast cancer, and spinal muscular atrophy.
Read on to review the status of these eleven potential blockbusters:
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right